Skip to content
The Injury Atlas
CYST

Hemorrhagic Cystitis

Bleeding inflammation of the bladder urothelium — classically acrolein injury from the oxazaphosphorines (prevented by mesna), but also reported as immune-related, intravesical-chemical, or radiation-recall injury.

1signature agents

Where it strikes

Bladder / Urothelium

Urine storage (outflow, not a nephron segment)

See it on the nephron

Agents’ overall severity

Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.

Mild· 1

Agents’ overall reversibility

Reversible· 1
Does the kidney recover? Cross-drug outcomes

Agents’ onset window

How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.

Variable· 1

Real-world reporting for this lesion

FAERS across all lesions →

How disproportionately hemorrhagic cystitis is reported for each agent in FAERS, against every other drug (reporting odds ratio, 95% CI; a signal needs the lower bound above 1, on at least 50 total reports for the agent) — a spontaneous-reporting signal, not incidence or proven causation. FAERS carries reporting and indication biases and has no denominator.

15Corroborated

Documented in the atlas profile and carrying a FAERS signal — the strongest claim the atlas makes.

0Documented, FAERS-silent

Documented in a profile with no reporting signal. Mostly expected: naming this lesion on a report can require a biopsy, or the agent has too few reports to divide.

49Not attributable

A real reporting signal that is not evidence for this drug-lesion pair: no MedDRA term names it, the naming subset asked alone came back flat, or the 2026-08 review attributed the reporting to the population, co-therapy, or class-level literature.

18Reported by name

The terms that name this lesion are disproportionate, but no profile documents it for that agent. Most are echoed by a sibling agent in the same class. Leads for review, never lesions the atlas claims.

Order
  1. PentostatinPurine analog (ADA inhibitor) · FAERS only20.58 (14.48–29.26) · n=33 Reporting signal.
  2. CabazitaxelTaxane12.50 (10.60–14.74) · n=148 Reporting signal.
  3. BusulfanAlkylator · FAERS only10.31 (9.47–11.23) · n=554 Reporting signal.
  4. Mitomycin CAntitumor antibiotic9.31 (7.74–11.20) · n=116 Reporting signal.
  5. FludarabinePurine analog · FAERS only6.73 (6.30–7.19) · n=911 Reporting signal.
  6. TeniposidePodophyllotoxin (topo II) · FAERS only6.56 (3.26–13.21) · n=8 Reporting signal, fragile (few reports).
  7. BicalutamideNonsteroidal antiandrogen · FAERS only6.14 (5.50–6.86) · n=323 * Reporting signal, on terms consistent with the lesion rather than naming it.
  8. PenpulimabPD-1 immune checkpoint inhibitor · FAERS only5.91 (1.46–23.99) · n=2 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
  9. ClofarabinePurine analog · FAERS only5.57 (4.13–7.51) · n=44 Reporting signal.
  10. ThiotepaAlkylator5.56 (4.81–6.42) · n=187 Reporting signal.
  11. Tisotumab vedotinAntibody-drug conjugate (tissue factor/MMAE) · FAERS only5.45 (3.33–8.94) · n=16 Reporting signal.
  12. AvelumabAnti-PD-L1 antibody · FAERS only3.63 (2.72–4.86) · n=46 * Reporting signal, on terms consistent with the lesion rather than naming it.
  13. SelpercatinibRET inhibitor · FAERS only3.53 (2.13–5.88) · n=15 * Reporting signal, on terms consistent with the lesion rather than naming it.
  14. CyclophosphamideOxazaphosphorine alkylator3.47 (3.33–3.63) · n=2,115 Reporting signal.
  15. IfosfamideOxazaphosphorine alkylator2.82 (2.46–3.23) · n=211 Reporting signal.
  16. GefitinibEGFR TKI2.68 (2.16–3.32) · n=84 Reporting signal.
  17. MitoxantroneAnthracenedione2.46 (1.88–3.22) · n=54 Reporting signal.
  18. DocetaxelTaxane2.28 (2.09–2.48) · n=539 Reporting signal.
  19. GemcitabineNucleoside analog1.60 (1.43–1.79) · n=302 Reporting signal.
  20. CarboplatinPlatinum agent1.59 (1.48–1.71) · n=722 Reporting signal.
  21. DoxorubicinAnthracycline1.58 (1.45–1.72) · n=535 Reporting signal.
  22. AtezolizumabAnti-PD-L1 antibody1.57 (1.36–1.81) · n=192 Reporting signal.
  23. PaclitaxelTaxane1.44 (1.32–1.57) · n=509 Reporting signal.
  24. CisplatinPlatinum agent1.42 (1.28–1.57) · n=392 Reporting signal.
  25. PembrolizumabPD-1 checkpoint inhibitor1.24 (1.13–1.37) · n=414 Reporting signal.

reporting odds ratio (log) — no signal left of the dashed line at 1.0

All 15 agents documented with CYST in the atlas are shown whether or not FAERS flags them, plus the 67 agents FAERS flags that the atlas does not document (marked “FAERS only”; the strongest 10 until you show all). 82 carry a reporting signal (filled dot: 95% CI lower bound above 1, on at least 50 reports for the agent); a signal on fewer than 10 reports of the disorder is hollow, on a dashed whisker. Grey marks are ratios that do not clear it. Signals are listed first, each group by ROR; * a signal carried by terms consistent with the lesion, not naming it. n = reports of the disorder for the agent. openFDA FAERS, as of 2026-11-15. A reporting signal, not incidence or causation, and no signal is not evidence of safety. Layout after the single-event rankings of Klomjit, Gupta et al.

Management approach

Full framework →

Prevent with mesna and hydration; this is an outflow (bladder) toxicity, not nephron injury.

Drug-level levers

  • Hold further dosing for significant hemorrhagic cystitis.
  • Co-administer mesna with ifosfamide and high-dose cyclophosphamide.

Pharmacologic toolkit

  • Mesna — Binds acrolein in the urine; standard prophylaxis with the oxazaphosphorines.
  • Hydration / bladder irrigation — Forced diuresis; continuous bladder irrigation for established hemorrhagic cystitis.

When to biopsy

Not a kidney-biopsy lesion; cystoscopy for severe or refractory bladder bleeding.

Monitoring

  • · Urinalysis for hematuria
  • · Symptoms of cystitis

Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.